XBI241206C101000
- 0.60
- -0.18-23.08%
SPDR S&P Biotech ETF Newsroom
Gilead Sciences Ticks Upward for the Eight Consecutive Session
Looking Into Natera's Recent Short Interest
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Trending Stocks This Week as Holiday Season Begins With Thanksgiving Break
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Trump has promised to significantly reduce corporate taxes! Who are the potential big winners of the tax cuts?
JPMorgan pointed out that companies in the S&P 500 index with an actual tax rate greater than 15% and 80% of revenue coming from the USA are potential beneficiaries of Trump's tax cuts policy, mainly concentrated in the financial and industrial sectors, followed by essential consumer, optional consumer, and medical care sectors.
Biotech ETF (XBI) Ended a Diagonal: Looking for Buying Dips
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Natera Announces Its Prospera Lung Test Has Met Coverage Requirements From The Centers For Medicare & Medicaid Services' Molecular Diagnostics Services Program For Single Lung Transplant Recipients; This Coverage Applies To SLT Patients In The...
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $202
Sarepta Therapeutics Analyst Ratings
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
(ABBV) - Analyzing AbbVie's Short Interest